ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2451

Prognostic Value of Functional Outcomes in a Italian Multicentric Cohort of Early SSc-ILD Patients

Chiara Bellocchi1, Alessandro Santaniello2, Silvia Bosello3, Enrico De Lorenzis4, Gerlando Natalello5, Nicoletta Del Papa6, Silvia Cavalli7, Devis Benfaremo8, Giacomo De Luca9, Corrado Campochiaro10, Lorenzo Cavagna11, Veronica Codullo12, Francesco Bonomi13, gaia Montanelli14, Adriana Severino15, Monica Caronni2, Martina Iacubino16, Barbara Vigone2, Silvia Bellando-Randone17, Carlomaurizio Montecucco18, Marco Matucci-Cerinic19, Lorenzo Dagna20, Gianluca Moroncini8, Roberto Caporali21 and Lorenzo Beretta22, 1Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, 2Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, MILANO, Italy, 3FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI- IRCCS, Rome, Rome, Italy, 4Catholic University of the Sacred Heart, Roma, Rome, Italy, 5Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, 6ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milano, Milan, Italy, 7University of Milan, Milan, Milan, Italy, 8Marche Polytechnic University, Ancona, Italy, 9Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, 10IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, 11University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, 12Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, 13Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, 14Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Italy, 15Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Milan, Italy, 16Università degli Studi di Milano, Milano, Italy, 17University of Florence, Florence, Florence, Italy, 18IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 19University San Raffaele Milano, Milano, Milan, Italy, 20Ospedale San Raffaele, Milano, Italy, 21Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 22Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy

Meeting: ACR Convergence 2024

Keywords: interstitial lung disease, prognostic factors, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc). Pulmonary function tests (PFTs) can serve as useful surrogate measures in monitoring SSc-ILD, providing valuable information about lung function and showing varying correlations with survival when evaluated longitudinally. Several thresholds have been proposed to define a meaningful decline in FVC, DLco, or both. While some measures, such as the composite OMERACT outcome measure, have demonstrated prognostic significance in randomized controlled trials, the relevance of others is still debatable. Similarly, their long-term prognostic implications are unclear.

Methods: SSc-ILD patients from seven Italian tertiary centers who met the following criteria were included: a) diagnosis of SSc (ACR/EULAR criteria); b) disease duration ≤5 years at the time of the first PFT; c) absence of ACA; d) evidence of ILD on HRCT. A prospective-retrospective data collection was performed, and 10-year survival estimates were evaluated via Cox regression models (respiratory-related causes of death). Time-dependent models were used to determine the significance of attaining functional outcomes defined as follows: a) either a relative FVC reduction of ≥ 10%, or a decline of ≥ 5% to < 10% in FVC accompanied by a relative ≥ 15% decline in DLco (OMERACT composite); b) an absolute FVC decline ≥ 5% predicted (labelled FVC5); c) an absolute FVC decline ≥ 5% predicted or an absolute DLco decline ≥ 10% predicted (labelled FVC5/DLco10).

Results: A total of 437 SSc-ILD patients with a median disease duration of 0.8 (0.2-2.2) years were included (Table1). A total of 35 (8%) SSc-ILD-related deaths were recorded within 10 years. Male gender, baseline FVC, or DLco % of predicted values were associated with worse survival, with optimal discriminative cutoffs for FVC < 80% or DLco ≤ 65%. The time-dependent Cox models, corrected for significant baseline covariates described above, showed that longitudinally, FVC was associated with reduced mortality hazards (HR=0.948 [0.9332-0.9625], p=1*10-11), being the strongest predictor of survival with an overall mortality risk of 3.5% for every individual FVC point decrease. Among the functional outcomes evaluated, the composite OMERACT outcome had the highest statistical significance (Table 2) compared to the FVC5 or FVC5/DLco10 outcomes.

Conclusion: In a large SSc-ILD population enriched with patients at risk for progression, baseline FVC, as well as its change over time, was shown to be a predictor of mortality. Our data indicate that among the proposed outcome measures, the composite OMERACT outcome had the best performance compared to other proposed measures, which seem of less use. These findings suggest the importance of close PFT monitoring over time and provide insights into the prognostic value of functional outcomes.

Supporting image 1

Table 1 – Baseline clinical characteristics

Supporting image 2

Table 2 – Time-dependent survival analysis


Disclosures: C. Bellocchi: None; A. Santaniello: None; S. Bosello: None; E. De Lorenzis: None; G. Natalello: None; N. Del Papa: None; S. Cavalli: None; D. Benfaremo: None; G. De Luca: Boehringer-Ingelheim, 6; C. Campochiaro: Boehringer-Ingelheim, 1, 6, Janssen, 6, Novartis, 1, 6; L. Cavagna: None; V. Codullo: None; F. Bonomi: None; g. Montanelli: None; A. Severino: None; M. Caronni: None; M. Iacubino: None; B. Vigone: None; S. Bellando-Randone: None; C. Montecucco: None; M. Matucci-Cerinic: None; L. Dagna: None; G. Moroncini: None; R. Caporali: AbbVie, 2, 6, Amgen, 2, 6, BMS, 2, 6, Celltrion, 2, 6, Fresenius Kabi, 2, Galapagos, 2, 6, Janssen, 2, 6, Lilly, 2, 6, MSD, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 2, Sandoz, 2, 6, UCB, 2, 6; L. Beretta: None.

To cite this abstract in AMA style:

Bellocchi C, Santaniello A, Bosello S, De Lorenzis E, Natalello G, Del Papa N, Cavalli S, Benfaremo D, De Luca G, Campochiaro C, Cavagna L, Codullo V, Bonomi F, Montanelli g, Severino A, Caronni M, Iacubino M, Vigone B, Bellando-Randone S, Montecucco C, Matucci-Cerinic M, Dagna L, Moroncini G, Caporali R, Beretta L. Prognostic Value of Functional Outcomes in a Italian Multicentric Cohort of Early SSc-ILD Patients [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/prognostic-value-of-functional-outcomes-in-a-italian-multicentric-cohort-of-early-ssc-ild-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prognostic-value-of-functional-outcomes-in-a-italian-multicentric-cohort-of-early-ssc-ild-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology